Tresquare Technologies srl

Who we are

Tresquare Technologies srl is an Innovative Biomedical Startup founded in December
2022. The startup aims to develop the first minimally invasive (transcatheter) and
innovative device for treating Aortic Stenosis (AS). The Co-Founders of this startup have
held prominent positions in Italian and foreign biomedical companies and have previously
founded successful biomedical Startups.
The Tresquare management team is composed of two engineers with ten years of
experience in Project Management/Finance as well as Regulatory/Clinical activities (Eng.
Stefano Pasquino – CEO and Co-Founder) and in the design of transcatheter implantable
medical devices, with solid expertise in CAD design and finite element simulation of
implantable Nitinol devices (Eng. Mauro Ferraro – CTO and Co-Founder). Both have had
professional experiences in Biomedical Companies and as Consultants, supporting
Startups in developing and certifying different medical devices.

What we do

Tresquare Technologies plans to develop the world’s first device for the mechanical
resection and removal of degenerated leaflets (with calcifications) of aortic bioprostheses
using a transcatheter interventional procedure (without extracorporeal circulation) that only requires limited access from the femoral artery. This minimally invasive technique would be used during Valve in Valve (ViV) procedures, where in clinical practice, a bioprosthesis with calcified leaflets is replaced with a new bioprosthesis that is implanted inside the diseased one, reducing the patient’s valve orifice (the calcified leaflets remain in place).
The success of this new device is guaranteed by a temporary valve support that keeps the
patient hemodynamically stable (in the absence of the removed valve leaflets) and waiting
for the implantation of a commercial TAVI (Transcatheter Aortic Valve Implantation).